DE-CSC
8.10.2020 12:02:07 CEST | Business Wire | Press release
CSC , a world leader in business, legal, tax, and domain security, today released new research from their Digital Brand Services (DBS) division that reveals areas of risk for prominent election-related websites. The research indicates that web domains closely linked to the campaign websites for Joe Biden and Donald Trump lack basic domain security protocols and are being targeted for disinformation activities such as domain spoofing, and threats including domain name and domain name system (DNS) hijacking, and phishing.
On the heels of its recent Forbes Global 2000 research , CSC is seeing major risks related to the manipulation of web properties that voters rely on for information and donations. Findings show that over 90% of these web properties are not using registry locks to protect their domains from domain and DNS hijacking that can lead to phishing attacks, network breaches, and email compromise.
“As noted in our previous research, we’ve consistently seen domains emerge as a threat vector for enterprises, and an area that is continuously overlooked in cyber security. Due to the sensitivity and importance of the U.S. election process, domain security remains a major vulnerability for the potential of foreign interference, fraud, and misinformation,” says Mark Calandra, executive vice president for CSC DBS. “As an organization with the most visibility into the domain landscape, we advocate for the sanctity of voter trust and encourage both presidential candidates and other websites in the electoral ecosystem to prioritize domain security on their websites to ensure security and build confidence.”
"We have reached the point where awareness is not enough. Those responsible for managing domain registrations, including registrars and hosting companies, need to have an actionable plan that is aligned with best practices. Additionally, experiences must be shared between those within the industry for the good of the wider internet community," said Matthew Stith, industry liaison at Spamhaus. “Without this commitment, users will be open to continued manipulation and fraud."
In April of 2020 when domain names were at the center of many COVID-19 related fraud schemes, Senators Mazie K. Hirono (D-Hawaii), Cory Booker (D-N.J.), and Maggie Hassan (D-N.H.) called on domain name registrars and hosting sites to combat scams and misinformation. CSC’s research shows that domain security and preventing domain spoofing continue to be an oversight even with top election-related web properties. Our research shows that more than 75% of these election-related domains are using retail-grade domain registrars, which do not provide advanced security protocols.
Our research also showed that, of the typo domains related to joebiden.com and donaldjtrump.com , 60% are still available for registration, thereby posing future threats. Additionally, more than a third of those presidential candidate typo domains are linked to third parties; of that one third, nearly 70%:
- Are configured to send and receive emails, which can be used to lure donors to phishing sites
- Were registered in 2020 leading up to the November election
- Disguise the owner’s identity behind proxy or privacy services
With cyber criminals subverting activities on these websites to disseminate misinformation or commit fraud against web visitors, there is also the threat of ransomware. Simon Chassar, chief revenue officer at NTT Ltd.’s Security division states, "NTT's September Monthly Threat Report identified ransomware as a significant threat to the U.S. election infrastructure. With DNS, domains, and email being a potential vehicle to distribute malicious content, our NTT Ltd. Security division suggests focus in this area, ensuring it is secure by design."
For additional details on these findings, visit the CSC blog “U.S. Election-Related Web Properties Prone to Fraud and Misinformation Due to Lack of Domain Security.”
Note: CSC aggregated this data using SimilarWeb.com for the period of August 1 – August 30, 2020.
About CSC
CSC is the trusted provider of choice for the Forbes Global 2000 and the 100 Best Global Brands® in enterprise domain names, domain name system (DNS), digital certificate management, as well as digital brand and fraud protection. As global companies make significant investments in their security posture, CSC can help them understand known security blind spots that exist and help them secure their digital assets. By leveraging CSC’s proprietary solutions, companies can get secure to protect against cyber threats to their online assets, helping them avoid devastating revenue loss, brand reputation damage, or significant financial penalties because of policies like the General Data Protection Regulation (GDPR). CSC also provides online brand protection—the combination of online brand monitoring and enforcement activities—taking a holistic approach to digital asset protection, along with fraud protection services to combat phishing. Headquartered in Wilmington, Delaware, USA, since 1899, CSC has offices throughout the United States, Canada, Europe, and the Asia-Pacific region. CSC is a global company capable of doing business wherever our clients are—and we accomplish that by employing experts in every business we serve. Visit cscdbs.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201008005203/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
